Neonatal AAV-SIL1 gene therapy prevents Marinesco-Sjögren syndrome in mice
- 1Istituto di Ricerche Farmacologiche Mario Negri IRCCS
Abstract
Marinesco-Sjogren syndrome is a rare early-onset multisystem disorder characterized primarily by cerebellar ataxia and myopathy and caused by loss-of-function mutations in SIL1. No disease-modifying therapy is available. We investigated whether adeno-associated virus (AAV)-mediated gene therapy could prevent neurological and muscular disease in the woozy mouse model of SIL1 deficiency. Neonatal mice received intracerebroventricular injections of AAV-PHP.eB vectors expressing SIL1 under the control of either a ubiquitous or a Purkinje cell-specific promoter. Vehicle-treated woozy mice developed progressive motor impairment accompanied by extensive Purkinje cell degeneration, thinning of the cerebellar molecular layer, marked astrogliosis and activation of endoplasmic reticulum stress pathways. In contrast, AAV-SIL1 treatment prevented the onset of ataxia and substantially preserved cerebellar architecture, including Purkinje cells and molecular-layer thickness, while reducing astrogliosis and endoplasmic reticulum stress. Selective restoration of SIL1 expression in Purkinje cells was sufficient to rescue motor performance, supporting a major cell-autonomous contribution of Purkinje cell dysfunction to cerebellar disease. Therapeutic benefit was maintained throughout the 26-week observation period, the longest time point examined, with treated mice remaining behaviorally indistinguishable from heterozygous controls. AAV-SIL1 treatment also improved muscle function and markedly attenuated skeletal muscle pathology, with transgenic SIL1 expression in muscle reaching levels comparable to those in heterozygous controls. These findings provide proof-of-principle that AAV-mediated SIL1 gene therapy can prevent the neurological and muscular manifestations of Marinesco-Sjogren syndrome and identify Purkinje cells as a critical cellular target for preventing cerebellar dysfunction.
Related
- Atypical Phenotype of Marinesco–Sjögren Syndrome with Predominant Myopathy due to a Novel SIL1 Variant
- Combined lactate and hypothermia therapy enhances neuroprotection following neonatal hypoxic-ischemic brain injury
- IgY-based passive immunity therapy significantly reduced neonatal calf diarrhea and Cryptosporidium spp. infection dynamics under field conditions
- SMCHD1 is a target for gene activation therapy to treat Prader-Willi syndrome
- Case Report: Targeted therapy for TIF1γ-positive dermatomyositis with possible macrophage activation syndrome, cardiac and gastrointestinal involvement: a case-based review
BibTeX
@misc{pasini2026neonatal,
title = {{Neonatal AAV-SIL1 gene therapy prevents Marinesco-Sjögren syndrome in mice}},
author = {C. Pasini and G. Lavigna and A. Grasso and E. Restelli and A. Corbelli and M. Salio and L. Zentilin and F. Fiordaliso and R. Chiesa},
howpublished = {bioRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.14.751587},
url = {https://www.biorxiv.org/content/10.64898/2026.09.14.751587v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Neonatal AAV-SIL1 gene therapy prevents Marinesco-Sjögren syndrome in mice
AU - C. Pasini
AU - G. Lavigna
AU - A. Grasso
AU - E. Restelli
AU - A. Corbelli
AU - M. Salio
AU - L. Zentilin
AU - F. Fiordaliso
AU - R. Chiesa
PY - 2026
DA - 2026/09/14
PB - bioRxiv
DO - 10.64898/2026.09.14.751587
UR - https://www.biorxiv.org/content/10.64898/2026.09.14.751587v1
AB - Marinesco-Sjogren syndrome is a rare early-onset multisystem disorder characterized primarily by cerebellar ataxia and myopathy and caused by loss-of-function mutations in SIL1. No disease-modifying therapy is available. We investigated whether adeno-associated virus (AAV)-mediated gene therapy could prevent neurological and muscular disease in the woozy mouse model of SIL1 deficiency. Neonatal mice received intracerebroventricular injections of AAV-PHP.eB vectors expressing SIL1 under the control of either a ubiquitous or a Purkinje cell-specific promoter. Vehicle-treated woozy mice developed progressive motor impairment accompanied by extensive Purkinje cell degeneration, thinning of the cerebellar molecular layer, marked astrogliosis and activation of endoplasmic reticulum stress pathways. In contrast, AAV-SIL1 treatment prevented the onset of ataxia and substantially preserved cerebellar architecture, including Purkinje cells and molecular-layer thickness, while reducing astrogliosis and endoplasmic reticulum stress. Selective restoration of SIL1 expression in Purkinje cells was sufficient to rescue motor performance, supporting a major cell-autonomous contribution of Purkinje cell dysfunction to cerebellar disease. Therapeutic benefit was maintained throughout the 26-week observation period, the longest time point examined, with treated mice remaining behaviorally indistinguishable from heterozygous controls. AAV-SIL1 treatment also improved muscle function and markedly attenuated skeletal muscle pathology, with transgenic SIL1 expression in muscle reaching levels comparable to those in heterozygous controls. These findings provide proof-of-principle that AAV-mediated SIL1 gene therapy can prevent the neurological and muscular manifestations of Marinesco-Sjogren syndrome and identify Purkinje cells as a critical cellular target for preventing cerebellar dysfunction.
ER -